FDA plans ultra-fast review of three psychedelic drugs following Trump directive
The Food and Drug Administration says it will offer ultra-fast review to three psychedelic drugs being studied for hard-to-treat mental health conditions, including major depression
April 24, 2026
Stabbing suspect due in court after night of anti-immigrant protests in Northern Ireland
Fear of Ukrainian drones empties the guesthouses in Latvia's Land of Blue Lakes
India bond-tax moves to catalyse foreign debt inflows, bolster bid for global index inclusion
Greece approves quicker migrant returns, aims to set up return hubs
Honda America recalls more than 880,000 vehicles over rear suspension components failure
Somali World Cup referee denied entry to US arrives home to hero's welcome